Duchenne muscular dystrophy (DMD) is the most common neuromuscular disease affecting boys. Advances in their care can delay the progression of DMD-related disability and prolong survival. The administration of glucocorticoids is among these advances. Glucocorticoid therapy, however, is associated with a myriad of potential adverse effects, and treating physicians as well as patients and their family members must understand the benefit/risk ratio of glucocorticoid therapy. Although current best evidence supports the use of glucocorticoids in patients with DMD, many are not offered the option. Considerable variability in practice also exists regarding when and how these drugs should be administered.
Address correspondence to Amparo Gutierrez, LSUHSC Department of Neurology, 1542 Tulane Avenue, Seventh Floor, New Orleans, LA 70112, email@example.com.
Relationship Disclosure: Dr England has served on the advisory board of Grifols, SA, and as editor-in-chief of the Journal of the Neurological Sciences. Dr Gutierrez has served on the advisory board of Biogen Idec and received compensation for speaking activities at Genzyme Corporation, Novartis, and Teva Pharmaceutical Industries Ltd.
Unlabeled Use of Products/Investigational Use Disclosure: Drs England and Gutierrez report no disclosures.